This approval was based on the SOPHIA study (NCT02492711), a phase III trial that compared margetuximab plus CT versus trastuzumab plus CT in 536 patients with HER2+ metastatic BC who had received at least two prior anti-HER2+ therapies [108,111]. This evidence concerns the gene ERBB2 and breast cancer.